Genitourinary Cancer News

Optimal sequencing of therapy for metastatic urothelial carcinoma will be crucial to extend patient survival, given the number of drug approvals over the past decade, according to a speaker at Chemotherapy Foundation Symposium.

Scientists from Denmark and the United States have engineered a yeast commonly used in foods to produce the precursor molecules for the anticancer agent vinblastine, a drug that has been in shortage several times in recent years.

Thromboembolism incidence appeared high among patients who received immunotherapy-based combinations for metastatic renal cell carcinoma, according to retrospective study results.

Treatment with CTX130, a novel chimeric antigen receptor T-cell therapy, led to disease control in more than three quarters of patients with advanced clear cell renal cell carcinoma, results from a phase 1 trial showed.

The addition of a cell-based immune primer to sunitinib exhibited activity among patients with metastatic renal cell carcinoma, according to randomized phase 2 study results.

Tivozanib improved long-term PFS compared with sorafenib among patients with relapsed or refractory advanced renal cell carcinoma, according to study results.

Most patients with renal cell carcinoma ineligible for surgery and ablation achieved tumor reduction after treatment with nivolumab plus ipilimumab, according to study results.

Many contemporary clinical trials for metastatic renal cell carcinoma incorporate restrictive eligibility criteria, according to study results.

The Kidney Cancer Association posthumously presented Nicholas J. Vogelzang, MD, FACP, FASCO, with a new award named in his honor.

Artificial intelligence models can help predict cardiotoxicity risk among patients with renal cell carcinoma treated with VEGF receptor inhibitors, according to study results.